https://www.selleckchem.com/pr....oducts/carfilzomib-p
Of note, both the total cost (the total inpatient and outpatient cost) and the index hospitalization costs were higher in patients treated with multiple antifungal drugs than in those treated with a single antifungal drug during the index hospitalization. Despite being at high IFI risk, 12% of the patients in the AML/MDS cohort did not receive antifungal drugs during the index hospitalization. Most patients with hematologic malignancy and high IFI risk underwent complicated antifungal management requiring use of multiple drug
Like
Comment
Share
